Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6199536 | Ophthalmology | 2015 | 7 Pages |
Abstract
These analyses suggest that there are subgroups of patients for whom VA outcomes in the second year of the VIEW studies were less stable than in the first year and for whom W52 seems to be an important inflection point. Although alternate reasons specific to the nature of the underlying AMD cannot be fully excluded, the switch in treatment regimen at W52 is a plausible explanation.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Gisbert MD, Jordi MD, PhD, Sebastian MD, PhD, Jean François MD, Robyn MBBS, PhD, Michaella MD, Christiane MS, Rupert MD, PhD, Oliver MD,